215 patents
Page 5 of 11
Utility
Protein Kinase B Inhibitors
14 Jul 22
Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
Filed: 16 Dec 21
Utility
PCSK9 Inhibitors and Methods of Use Thereof
14 Jul 22
The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof.
Michael H. SERRANO-WU, Mark CHAMBERS, Erica GOLDSMITH, Jason TIERNEY, Karamjit JANDU, David CLARK, Paul HINCHLIFFE
Filed: 20 Dec 21
Utility
Fused Tricyclic Compounds Useful As Anticancer Agents
30 Jun 22
Jason Grant KETTLE, Iain SIMPSON, Christopher PHILLIPS, Scott BOYD, Oliver Ross STEWARD, Michael Steven BODNARCHUK, Doyle Joseph CASSAR, Kurt Gordon PIKE
Filed: 3 Mar 20
Utility
Lipocalin Mutein for Treatment of Asthma
23 Jun 22
The present invention relates to the treatment of asthma in a human subject by administering by inhalation a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, to said subject, wherein the delivered dose of said lipocalin mutein, or variant or fragment thereof, is from about 0.1 mg to about 160 mg.
Lena Therese AXELSSON, David Robert CLOSE, Philip GARDINER, Aulikki Ingergard Alexandra JAUHIANINEN, Ekaterina PARDALI, Mary FITZGERALD, Gabriele MATSCHINER, Ingmar BRUNS, Gunnel Marita OLSSON
Filed: 25 Mar 20
Utility
ANTI-IL5R Antibody Formulations
23 Jun 22
Provided herein are anti-IL5R antibody formulations containing an amount of surfactant below critical micelle concentration (CMC) of the surfactant and methods of using such formulations.
SABA GHAZVINI, CASSANDRA MANKUS
Filed: 16 Dec 21
Utility
Osimertinib for Use In the Treatment of Non-small Cell Lung Cancer
16 Jun 22
The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III)), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.
Anthony Francis Patrick NASH
Filed: 27 Oct 21
Utility
IRAK4 Inhibitors
16 Jun 22
Ina TERSTIEGE, Stefan SCHIESSER, Yafeng XUE, Hui-Fang CHANG, Anna Ingrid Kristina BERGGREN
Filed: 1 Dec 21
Utility
Lanabecestat for Weight Loss
9 Jun 22
The present application relates to affecting weight loss comprising administering a therapeutically effective amount of (1r,1′R,4R)-4-methoxy-5″-methyl-6′-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3′H-dispiro[cyclohexane-1,2′-indene-1′,2″-imidazol]-4″-amine, or a pharmaceutically acceptable salt thereof (e.g., the camsylate salt of (1r,1′R,4R)-4-methoxy-5″-methyl-6′-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3′H-dispiro[cyclohexane-1,2′-indene-1′,2″-imidazol]-4″-amine).
Craig SHERING, John SIMS
Filed: 13 Mar 20
Utility
Osimertinib for Use In the Treatment of Non-small Cell Lung Cancer
9 Jun 22
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.
Anthony Francis Patrick NASH
Filed: 27 Mar 20
Utility
Estrogen Receptor Degrading Protacs
2 Jun 22
Bin YANG, Thomas George Christopher HAYHOW, Charlene FALLAN, James Stewart SCOTT, Coura Rosalie DIENE, Bernard Christophe BARLAAM, Johannes Wilhelmus Maria NISSINK
Filed: 27 Mar 20
Utility
Mpo Inhibitors for Use In Medicine
26 May 22
The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same.
Andrew WHITTAKER, Hitesh Jayantilal SANGANEE
Filed: 2 Dec 21
Utility
Type I Interferon-mediated Disorders
26 May 22
The invention provides methods of identifying, diagnosing, treating, and monitoring or prognosing progression of type I IFN-mediated disease or disorder in subjects.
Kerry CASEY, Dominic SINIBALDI, Michael SMITH, Miguel SANJUAN
Filed: 14 Feb 20
Utility
Compositions and Methods for Improved Gene Editing
26 May 22
The present disclosure provides methods of introducing site-specific mutations in a target cell and methods of determining efficacy of enzymes capable of introducing site-specific mutations.
Marcello MARESCA, Songyuan LI
Filed: 9 Apr 20
Utility
Certain (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES for Treating Bronchiectasis
5 May 22
Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Reinilde HEYRMAN, Eugene SULLIVAN, Carlos FERNANDEZ
Filed: 14 Jan 22
Utility
Heteroaryl Compounds That Inhibit G12C Mutant Ras Proteins
28 Apr 22
Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Scott BOYD, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Piotr Antoni RAUBO
Filed: 5 Oct 21
Utility
Method of Treating Fibrosis
21 Apr 22
The present disclosure concerns certain Src kinase inhibitors, or pharmaceutically-acceptable salts thereof, and their use in the treatment of fibrosis and fibrotic conditions, such as idiopathic pulmonary fibrosis, in a warm-blooded animal such as a human.
Leslie COUSENS, Chad NIVENS, Katherine Jane ESCOTT, Susan MONKLEY, Antje PRASSE
Filed: 26 Feb 20
Utility
Automated Detection of Safety Signals for Pharmacovigilance
31 Mar 22
An embodiment may involve obtaining a set of pre-defined features and a new document; extracting a subset of the pre-defined features from within new document; applying a natural language model to the new document, wherein the natural language model was pre-trained using scientific or medical literature and fine-tuned using a corpus of documents; applying a feature-based model to the subset of the pre-defined features extracted from the new document, wherein the feature-based model was trained with the pre-defined features and the respective labels of the documents; and applying an aggregation model to the classifications of the new document produced by the natural language model and the feature-based model, wherein the aggregation model was trained with prior classifications produced by the natural language model and the feature-based model so that the aggregation model produces a further classification of the new document representing its relevance to pharmacovigilance.
Alexandre Kiazand, Robert Hernandez, Antoni Wisniewski, Douglas Domalik, Tony Gill
Filed: 22 Jul 21
Utility
Pharmaceutical Composition
24 Mar 22
The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
Filed: 6 May 21
Utility
Method of Treating Fatty Liver Disease
24 Mar 22
The present disclosure provides methods of treating or preventing fatty liver disease and/or lowering cholesterol and LDL cholesterol levels in a subject.
Daniel LINDEN, Richard LEE, Stefano ROMEO, Huynh-Hoa BUI
Filed: 21 Sep 21
Utility
Compositions and Methods for Treating Late Stage Lung Cancer
10 Mar 22
Disclosed are methods for treating late stage (e.g., clinical stage III or IV), unresectable non-small-cell lung cancer (NSCLC) with an antibody that inhibits PD1/PD-L1 activity in a patient identified as having not progressed following definitive chemoradiation therapy.
Giovanni Melillo, Marc Ballas, Simon Dovedi, Ross Stewart
Filed: 18 Nov 21